Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255

Lichtman, S. M.; Niedzwiecki, Donna; Barcos, M.; Carlisle, Thomas; Cooper, M. Robert; Johnson, Jackie; Peterson, Bruce A.

doi:10.1023/a:1008395400069

Cited by 13 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As mentioned above, paclitaxel and vinblastine, while also known to be cardiotoxic, are less toxic than anthracyclines and are usually reversible ( Lichtman et al, 2000 ; Gallego-Jara et al, 2020 ); therefore, although there are marketed nanomaterials based on them, the main indicators of investigation in the clinical trials do not include an evaluation of cardiac toxicity. In fact, this is a good direction to expand the content of clinical trials, whether in real-world studies of marketed varieties or phase II/III clinical studies of unmarketed varieties.…”

Section: Discussionmentioning

confidence: 99%

“…Vincristine is mainly used for the treatment of acute lymphoblastic leukemia, but it is also effective in other acute leukemias, Hodgkin’s disease, lymphosarcoma, reticulocyte sarcoma, and breast cancer. Vincristine is a cell cycle–specific drug and is often required in combination antitumor regimens with cell cycle non-specific drugs; therefore, most of the clinical data collected on the cardiotoxicity of vincristine are on its co-action with other chemotherapeutic agents ( Lichtman et al, 2000 ). Damage to blood vessels (e.g., phlebitis) is one of the most important side effects of vinblastine ( de Lemos, 2005 ).…”

Section: Antitumor Drugs Extracted From Plantsmentioning

confidence: 99%

See 1 more Smart Citation

Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?

Jiang

Yong-ming

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Cancer is one of the leading causes of death worldwide, and with the continuous development of life sciences and pharmaceutical technology, more and more antitumor drugs are being used in clinics to benefit cancer patients. However, the incidence of chemotherapy-induced cardiotoxicity has been continuously increasing, threatening patients’ long-term survival. Cardio-oncology has become a research hot spot, and the combination of nanotechnology and biomedicine has brought about an unprecedented technological revolution. Nanomaterials have the potential to maximize the efficacy and reduce the side effects of chemotherapeutic drugs when used as their carriers, and several nano-formulations of frequently used chemotherapeutic drugs have already been approved for marketing. In this review, we summarize chemotherapeutic drugs that are highly associated with cardiotoxicity and evaluate the role of nano-delivery systems in reducing cardiotoxicity based on studies of their marketed or R&D nano-formulations. Some of the marketed chemotherapy drugs are combined with nano-delivery systems that can effectively deliver chemotherapy drugs to tumors and cannot easily penetrate the endothelial barrier of the heart, thus decreasing their distribution in the heart and reducing the cardiotoxicity to some extent. However, many chemotherapy nanomedicines that are marketed or in R&D have not received enough attention in determining their cardiotoxicity. In general, nanomedicine is an effective method to reduce the cardiotoxicity of traditional chemotherapy drugs. However, cardiovascular complications in cancer treatment are very complex diseases, requiring the application of multiple measures to achieve effective management and prevention.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Antitumor Drugs Extracted From Plantsmentioning

confidence: 99%

Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?

Jiang

Yong-ming

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…They reported a 48% response rate with a 17% CR rate and a 6-month progression-free survival rate of 24%. 20 In the case of paclitaxel, mechanisms of action against tumor angiogenesis may be active with this low-dose, but more consistent-exposure regimen. Evidence that angiogenesis is important in the progression of lymphoma is mounting.…”

Section: Discussionmentioning

confidence: 99%

Low‐dose weekly paclitaxel for recurrent or refractory aggressive non‐Hodgkin lymphoma

Rizzieri

Sand

McGaughey

et al. 2004

Cancer

View full text Add to dashboard Cite

BACKGROUND. Many patients with recurrent, intermediate or high-grade non-Hodgkin lymphoma (NHL) may not respond to or are not candidates for aggressive salvage chemotherapy. Effective, less toxic regimens are needed. Although highdose taxanes have not been reported to be very effective for the treatment of lymphoma, different delivery rates may allow for different mechanisms of action to be manifest and result in a different toxicity profile and response rate. The current study tested this hypothesis by using low-dose, weekly paclitaxel in patients with recurrent or refractory NHL. METHODS. Adults age Ͼ 18 years with refractory or recurrent, aggressive NHL who were not considered curable with standard high-dose therapy received paclitaxel at a dose of 80 mg/m 2 weekly for 5 weeks for 2 cycles. RESULTS. Thirty-four patients with refractory NHL and 4 patients with recurrent disease were treated. Approximately 45% of the patients had achieved a prior disease remission. The median number of prior regimens received was 3, 74% of the patients had an International Prognostic Index of Ն 3 at the time of study entry, and 29% had failed high-dose therapy with autologous hematopoietic support. Only one patient encountered severe toxicity (sepsis). Myelosuppression was reported to occur in approximately 20% of patients. A total of 10 patients (26%) achieved a complete disease response and 4 patients (11%) achieved a partial response. CONCLUSIONS. In the current study, low-dose, weekly paclitaxel therapy was found to provide a well tolerated and less toxic approach to the treatment of refractory NHL, with encouraging responses noted in heavily pretreated patients. However, evaluation in patients with an earlier stage of disease is warranted. Cancer 2004;

show abstract

“…There was no benefit to the addition of either bleomycin or high-dose methotrexate. Other combinations were studied in patients who were refractory to CHOP or similar regimens (22). These data suggested that the addition of other drugs would not add to the activity of CHOP as had already been proposed (23).…”

Section: Diffuse Large B-cell Lymphomamentioning

confidence: 95%

The Cancer and Leukemia Group B Lymphoma Committee

Cheson¹,

Canellos²

2006

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255

Abstract: I-CHOPE can induce responses in this group of patients with a poor prognosis, but most were seen in those who had previously had a response to bolus chemotherapy.

Cited by 13 publications

References 17 publications

Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?

Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?

Low‐dose weekly paclitaxel for recurrent or refractory aggressive non‐Hodgkin lymphoma

The Cancer and Leukemia Group B Lymphoma Committee

Contact Info

Product

Resources

About